https://www.shuttlepharma.com/
|
Shuttle Pharmaceuticals develops radiation sensitizing drugs to improve the outcomes of patients undergoing radiation therapy for cancer treatment. Clinical phase drug candidates include ropidoxuridine for sensitizing rapidly growing tumors and doranidazole for sensitizing hypoxic cancers that are resistant to radiation therapy. |
|
